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Abstract
the epidemiology of MRsa pneumonia varies across
countries. one of the most import risk factors for the
development of nosocomial MRsa pneumonia is me-
chanical ventilation. Methicillin resistance in S. aureus
ventilator associated pneumonia (VaP) ranged between
37 % in german, 54 % in the us american and 78 %
in asian and latin american Icus. In 2009, the inci-
dence  density  of  nosocomial  VaP  caused  by  MRsa
was 0.28 per 1000 ventilation days in a network of 586
german Icus. Incidences peaked in neurological and
neurosurgical Icus. crude hospital mortality in studies
performed after 2005 lay between 27 % and 59 % and
attributable MRsa pneumonia mortality at 40 %. since
2005, us american and german data indicate decreas-
ing trends for MRsa pneumonia. Measures to reduce
MRsa pneumonia or to control the spread of MRsa
include  hand  hygiene,  standard  and  contact  precau-
tions, oral contamination with chlor  hexidine, skin de-
contamination with antiseptics, screening, and (possi-
bly) patient isolation in a single room. 
Key words: methicillin resistant staphylococcus aureus,
pneumonia,  nosocomial,  mortality,  risk  factor,  age,
change over time
1. INtRoductIoN
Pneumonia is the second most common hospital-ac-
quired (nosocomial) infection; in intensive care units
(Icu)  it  ranges  even  first  [1,  2].  the  prevalence  of
pneumonia varies, with an incidence ranging from 7 %
to  more  than  40  %.  In  ventilated  patients,  rates  of
pneumonia  may  be  between  6  and  21  times  higher
than in other patients, and the risk increases by 1 %
for each day the patient requires tracheal intubation
[3]. It is associated with prolonged hospital stays and a
high mortality rate and it differs by type of pathogen
[4, 5].
S.  aureus is  one  of  the  most  frequently  isolated
pathogens in nosocomial pneumonia and is problem-
atic due to its ubiquity (with up to 50 % persistent or
intermittent  colonized  adults  and  colonized  persons
being at increased risk for subsequent infection) and
its  production  of  extracellular  enzymes  and  toxins,
which function as virulence factors. 
MRsa is even more problematic because therapeu-
tic options to treat MRsa infections are limited be-
cause MRsa tends to be multiresistant i.e. not only re-
sistant  to  all  b-lactams  but  also  to  other  antibiotic
classes such as the fluoroquinolones.
the aim of our study was to give an overview on
nosocomial  MRsa  pneumonia  focusing  on  the  epi-
demiology and to present current ventilator-associated
pneumonia data of a network of 586 german Icus. 
2. EPIdEMIology
Based on the data of the german national nosocomial
infection surveillance system (kIss) about 20,000 ven-
tilator associated lower respirator tract infections can
be expected annually in german intensive care units,
among them about 16,000 cases of ventilator associat-
ed pneumonia (VaP) [6].  20 % of these cases are due
to S. aureus, and 37 % of them are methicillin resis-
tant (table 1). this means that about 1,200 ventilator-
associated pneumonia (VaP) cases due to MRsa can
be expected every year in german Icus.  Projecting
these figures to the whole European union would re-
sult in about 7,500 VaP cases with MRsa on Euro-
pean Icus annually. 
the mean VaP rate in medical-surgical Icus was
2.2  per  1000  ventilator  days  in  us-american  Icus
(2006-2008); it was higher with 4.8 in german Icus
(2005-2009) and was highest with 14.7 in Icus partici-
pating in the International Infection control consor-
tium (INIcc) [7, 8]. INIcc was founded in argentina.
countries providing data to INIcc from n > 10 Icus
are located in argentina, Brazil, colombia, India, Mex-
ico, Peru and turkey.
Interestingly,  S.  aureus ranged  first  as  causing
patho  gen in the usa and in germany and accounted
for 24.4 % and 19.8 % of the VaP cases, but it ranged
only third after Pseudomonas and Acinetobacter in the
latin-american and asian Icus (table 1) [9]. only re-
cently  there  is  increasing  evidence  that  temperature
and seasonality influences infection and colonization
with gram-negatives [10-12]. although S. aureus was
isolated in a smaller proportion in Icus from asia and
latin-america the percentage of MRsa on the total
of VaP cases caused by S. aureus was extremely high
with 77.5 %. More than half of the S. aureus pneu-
monia  cases  in  us-Icus  were  methicillin  resistant,
whereas only one third in german Icus. 
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pneumonia differ by geographic region and generaliza-
tion has to be done with caution and might be mis-
leading. 
furthermore,  it  was  in  the  1990s  when  MRsa
emerged as a community-associated pathogen. Espe-
cially  in  the  united  states  community-associated
MRsa strains have increasingly caused hospital-onset
and  health  care–associated,  community-onset  infec-
tions [13]. the initial usa400 strains that predominat-
ed before 2001 have now been replaced by the unrelat-
ed usa300 strains that currently cause the majority 
of  community-associated  MRsa  infections  [14]. 
In  some  countries  like  the  us,  canada  or  greece,
MRsa is increasing in the community and, in some
cases,  is  replacing  “nosocomial”  MRsa  in  hospitals
[15, 16].
Epidemiological data on nosocomial pneumonia in
non-Icu  patients  are  scare  and  it  remains  unclear
whether or not data from Icu patients can be used in
analogy. one of the few multicenter studies on noso-
comial pneumonia in non-Icus patients revealed that
S. pneumoniae accounted for 27 % (16 out of 59 pa-
tients)  but  S.  aureus for  only  7  %  (4  patients;  one
MRsa) of nosocomial pneumonia in patients where 
a  pathogen  could  be  isolated  [17].  the  authors  dis-
cussed that patients in conventional hospital wards are
not exposed to such invasive manoeuvres as patients
receiving mechanical ventilation; thus, changes in the
oropharyngeal  flora  are  probably  delayed  and 
the community flora persists longer in them. accord-
ingly, it can be hypothesized that microorganisms re-
sponsible for pneumonia acquired in the general hos-
pitalization wards may differ from those implicated in
VaP.
But, incidence densities on VaP caused by S. aureus
and MRsa differ even by type of Icu as shown in
figure 1. In neurosurgical and neurological Icus S.
aureus was  found  in  about  one  third  of  all  VaPs
whereas  it  played  only  a  minor  role  as  causative
pathogen in cardiothoracic Icus. the reason for this
might be the higher proportion of patients with heavy
aspiration (including aspiration of the nasopharyngeal
flora which serves as the reservoir of S. aureus) due to
neurotrauma or dysphagia in neurological and neuro-
surgical wards. the comparably small incidence in car-
diothoracic Icus might be explained by perioperative
prophylaxis with glycopeptides in centers with a high
endemic MRsa situation.
3. causE, PatHoPHysIology aNd RIsk
factoRs
MRsa like other bacteria can reach the lower respira-
tory tract to cause pneumonia by four routes: aspira-
tion,  inhalation,  contiguous  spread  and  haematoge-
nous spread. aspiration is the main route used by bac-
teria  to  invade  the  lower  airways  and  cause  VaP.
Haematogenous or contiguous routes of invasion are
very rare. 
the  impact  of  S.  aureus on  the  airways,  from
asymptomatic colonisation to severe pneumonia, de-
pends on the interplay of patient, bacterial and envi-
ronmental factors. colonisation of the lower respira-
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2 Meyer##_Umbruchvorlage  23.11.10  11:54  Seite 515tory tract by S. aureus (MRsa) can occur in the set-
ting of chronic pulmonary disease [18]. although this
colonisation may be asymptomatic, it paves the way
for overt infection, i.e. pneumonia, if the balance be-
tween host defence and bacterial virulence is shifted
in the favour of bacteria. colonisation can also occur
due to breaches in natural defences, such as endotra-
cheal intubation. those patients are sedated, or even
paralyzed,  and  cannot  cough  efficiently.  the  secre-
tions pool above the inflated endotracheal tube cuff
and  can  be  aspirated  if  not  drained  effectively.  Pa-
tients with head injury and trauma who have nasopha-
ryngeal carriage of S. aureus are at increased risk of
S. aureus pneumonia. staphylococcal pneumonia may
also develop after influenza infection or after novel
H1N1 influenza, which seems to occur preferentially
among young adults (in whom mortality reaches 50
%) [19]. 
known risk factors for MRsa infection in general
encompass  prior  antibiotic  use  especially  the  use  of
quinolones, enteral feeding, surgery and previous hos-
pitalization [20]. the time from Icu admission to in-
fection  differed  significantly  between  Mssa  and
MRsa in our network of 586 Icus: it was 14 days for
VaP caused by MRsa but only 8 days for VaP caused
by Mssa. other studies found even more prominent
differences in the length of hospital stay until the on-
set of pneumonia (4 days for Mssa and 11.5 days for
MRsa) [21].
4. agE aNd MoRtalIty
In most studies performed before 2005, patients with
MRsa pneumonia were older than patients with Mssa
pneumonia (table 2).  whether a greater number of
older patients with severe underlying diseases or other
patient differences have an impact of methicillin resis-
tance on morbidity and mortality among patients with
S. aureus pneumonia remains highly controversial. for
bacteraemia the increased mortality was shown in two
meta-analyses [22, 23], and the enormous influence on
morbidity and hospital costs was also demonstrated for
surgical site infections [24]. But for pneumonia it is still
debated whether MRsa causing VaP is an indepen-
dent risk factor for adverse outcomes. 
Rello et al. found a significantly higher mortality for
MRsa pneumonia in comparison to methicillinsuscep-
tible S. aureus (Mssa) pneumonia [25]. other authors
though, did not find that MRsa infections significantly
influenced  mortality  rates  [26-28].  deRyke  reported
that although fewer patients with MRsa pneumoniare-
ceived appropriate treatment (50 %) than patients with
Mssa pneumonia (72 %) neither the hospital mortality
differed, nor infection related mortality nor infection
related length of stay [21]. a systematic review to deter-
mine the effect of methicillin resistance on mortality in-
cluding eight articles was published in 2008[29]. crude
in-hospital mortality was higher in patients with VaP
due to MRsa than in those with VaP due to methicillin
sensitive S. aureus. likewise in our network of kIss
Icu the crude Icu fatality was significantly lower for
VaP caused by Mssa than by MRsa (table 2). How-
ever, adjustment for risk factors suggests that this asso-
ciation may not be causal, but probably due to con-
founders, such as the adequacy of empirical treatment
and severity of illness. this is underlined by the fact
that two recent studies with results on infection related
mortality did not reveal a significant difference [21, 27].
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Mssa methicillin susceptible s. aureus;  n number Icus.
Fig. 1. Incidence density of most frequently isolated pathogens associated with ventilator associated pneumonia per1000venti-
lator days by type of intensive care unit, 586 german Icus, 2005-2009. Fig. 1. Incidence density of most frequently isolated
pathogens associated with ventilator associated pneumonia per 1000 ventilator days by type of intensive care unit, 586 german
Icus, 2005-2009. 
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required significantly longer respiratory support than
VaP due to other organisms [30]. shorr et al. showed
also that MRsa patients on average consumed excess
resources of 4.4 overall mechanical ventilation days,
3.8 days of inpatient length of stay, 5.3 Icu days and
us 7,731 dollars total costs after controlling for case
mix and other factors [31]. Interestingly, the same au-
thor  published  5  years  later  that  total  charges  for
MRsa  health  care  associated  pneumonia  were  even
lower than those for Mssa pneumonia. However, to-
tal cost almost doubled within 5 years for MRsa as
well as for Mssa pneumonia [32, 33]. 
In general, the outcome of patients with pneumo-
nia due to either MRsa or Mssa is associated with a
significant morbidity, mortality, and health care cost,
even when the initial antibiotic therapy is adequate. 
5. cHaNgE oVER tIME
a recent study by kallen et al. on health care associat-
ed invasive MRsa infections in the usa, 2005-2008,
suggests  that  there  may  be  an  ongoing  decrease  in
MRsa as a cause of human infection, particularly in
non  community  settings  [34].  the  incidence  rate  of
hospital-onset invasive MRsa infections was 1.02 per
10,000 population in 2005 and decreased by 9.4 % per
year. the decrease was most prominent MRsa blood
stream infections but it was also statistically significant
for hospital onset of pneumonia or emphysema due to
MRsa. the National Healthcare safety Network re-
port states that the ranking of the 4 most common
pathogens was in 2006-2007 almost identical to that in
the NNIs report published in 1999 for VaP [9, 35].
the exception was a. baumannii that equalled lastly
Enterobacter species for VaP; S.  aureus remained in
the first position.
In  the  Icus  participating  in  kIss  there  was  no
change towards more gram-negatives or gram-posi-
tives in the incidence density of VaP pneumonia over
the last five years (fig. 2). S.  aureus ranged first as
causing pathogen from 2005-2009 and the proportion
of MRsa stayed stable accounting for about one third
of all S. aureus isolates. generally, the incidence densi-
ty of nosocomial VaP declined (from 5.81 in 2005 to
4.33 VaP per 1000 ventilation days in 2009) but the
decline affected all pathogens (from 5.76 in 2005 to
4.21  VaP-pathogens  per  1000  ventilation  days  in
2009). likewise reported Moalla et al. no trends in the
incidence  of  nosocomial  MRsa  pneumonia  in  a
french university hospital over a period of 4 years: it
was 0.9 cases per 1000 patient days in 2003 and was
0.7 in 2006 (p=.26) [36].
6. aNtIBIotIc tHERaPy aNd IMPact oN
EPIdEMIologIcal PaRaMEtERs
Pneumonia caused by MRsa has been recognized as a
difficult  to  treat  infection  because  of  the  limited
choice  of  therapy  and  prolonged  duration  of  treat-
ment. antibiotic therapy is needed for more than 14
or even 21 days in patients without rapid resolution of
symptoms, in bacteremic patients with metastatic in-
fections,  with  empyema  or  caverns  [37].  currently,
only vancomycin and linezolid are approved for thera-
py of MRsa pneumonia in the usa, in some Euro-
pean countries also teicoplanin and quinupristin / dal-
forpristin [38].
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crude Icu-mortality in patients with MRsa associated VaP was 24.6%, 26.9%, 24.9%, 32.1% and 26.3% for the years 2005 to
2009.
Mssa methicillin susceptible s. aureus, VaP ventilator-associated pneumonia
Fig. 2. Incidence densities (patho  gens per 1000 ventilator days) and proportion of the most frequently isolated pathogens in
ventilator associated pneumonia, 586 german Icus, 2005-2009
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trials compared linezolid to gycopeptides for MRsa
nosocomial pneumonia [39]. the results did not sup-
port the assertion that linezolid is a more efficacious
antibiotic.  clinical  and  microbiological  outcomes  in
patients  randomized  to  linezolid  were  not  superior 
to  patients  randomized  to  glycopeptides.  further-
more,  adverse  events  were  not  statistically  different
between  the  two  antibiotics.  the  authors  argue
against widespread routine use of linezolid for sus-
pected nosocomial MRsa pneumonia based on the
presumption  of  superior  efficacy.  they  recommend
that decisions between linezolid or glycopeptide an-
tibiotics  for  empiric  or  MRsa-directed  therapy  of
nosocomial  pneumonia  depend  on  local  availability,
antibiotic resistance patterns, preferred routes of de-
livery,  and  cost  (about  tenfold  increase  in  cost  per
dose linezolid), rather than presumed differences in
efficacy.
older agents such as fosfomycin, rifampicin and fu-
sidic acid in combination with vancomycin are theo-
retically effective. this has been supported by recent
studies [40, 41]; however, clinical trials from random-
ized controlled trials are lacking and will probably nev-
er be performed because of absent incentive for the
pharmaceutical industry (relatively inexpensive antibi-
otics).
whether or not the approval of linezolid in 2000 or
other new anti-MRsa antibiotics had an impact on the
epidemiology of MRsa remains unclear. a large-scale
canadian study included a 1.2 million population in
the province of alberta, canada, over a period of 7
years and monitored bacteremic S.  aureus infection:
the incidence of, and outcomes associated with S. au-
reus bacteremia have not significantly changed during
2000–2006.  the  overall  annual  incidences  for  bac-
teremia due to Mssa or MRsa, were 17.5 and 2.2 cas-
es/100,000  population/year,  respectively.  although
rates of both health care–associated community onset
and  nosocomial  Mssa  bacteremia  were  not  signifi-
cantly different throughout the duration of the study,
rates of community acquired Mssa bacteremia gradu-
ally  decreased  (p  =  .01).  But,  rates  of  MRsa  bac-
teremia increased (p= < .001). likewise, the popula-
tion mortality rate associated with MRsa bacteremia
was increasing during the study, however no signifi-
cant overall increase in the rate of death due to S. au-
reus bacteremia was observed [16]. 
In  our  data,  crude  Icu  mortality  due  to  MRsa
pneumonia did not decrease from 2005 to 2009. It was
24.6 % in 2005 and 26.3% in 2009. the overall inci-
dence density for nosocomial VaP decreased, but the
proportion of VaP due to MRsa or Mssa stayed sta-
ble (table 2).
7. PREVENtIoN of MRsa PNEuMoNIa
one of the most important risk factors for the devel-
opment of nosocomial pneumonia is mechanical ven-
tilation because the endotracheal tube holds the vocal
cords open and facilitates aspiration. all measures to
reduce VaP will have an impact also on MRsa pneu-
monia as well as all measures to prevent transmission
of MRsa in the hospital.
BuNdlE aPPRoacH foR tHE PREVENtIoN of VaP
a number of different care bundles have previously
been  implemented  to  prevent  VaP.  the  most  com-
monly used is supported by the 100,000 lives cam-
paign and comprises interventions of: Elevation of the
head of the bed to between 30 and 45 degrees, daily
sedation vacation and daily assessment of readiness to
extubate,  peptic  ulcer  disease  prophylaxis  and  deep
vein thrombosis prophylaxis (unless contraindicated).
this care bundle has reported considerable success in
reducing the incidence of VaP [42, 43]. However, cer-
tain recommendations are not strongly supported by
the available evidence or do not directly target VaP.
addressing this point, an European care bundle for
prevention  of  ventilator-associated  pneumonia  was
published only recently focusing on 5 points [44]:  (1)
Not  implementing  ventilatory  circuit  changes  unless
specifically indicated (2) the use of strict hand hygiene
using  alcohol  (3)  the  use  of  appropriately  educated
and trained staff (4) the incorporation of sedation va-
cation and weaning protocols into patient care and (5)
oral care with chlorhexidine.
oRal caRE wItH cHloRHExIdINE (RINsE oR gEl)
colonization of the oropharyngeal cavity with poten-
tially  pathogenic  micro-organisms  is  instrumental  in
the pathogenesis of VaP, and oropharyngeal deconta-
mination with antiseptics, such as chlorhexidine glu-
conate has been associated with reduced incidences of
VaP.  chlorhexidine  has  a  broad  range  of  activity
against gram-positive microorganisms, including mul-
tiresistant  pathogens  such  as  methicillin-resistant  S.
aureus (MRsa) [45]. koeman et al. found a risk reduc-
tion  of  VaP  by  65  %  if  oral  decontamination  was
done  with  chlorhexidine  in  comparison  to  placebo
[46]. the combination of chlorhexidine and colistin
provided significant reduction in oropharyngeal colo-
nization  with  both  gram-negative  and  gram-positive
microorganisms,  whereas  chlorhexidine  alone  mostly
affected  gram-positive  microorganisms.  likewise,
scannapieco and colleagues investigated differences in
oropharyngeal colonization between mechanically ven-
tilated patients receiving oropharyngeal decontamina-
tion with oral topical 0.12 % chlorhexidine either once
or twice daily compared to placebo. chlorhexidine did
reduce the number of S.  aureus in dental plaque of
trauma intensive care patients, but the study was un-
derpowered to demonstrate a reduction in VaP inci-
dence [47]. 
skIN dEcoNtaMINatIoN
the two most commonly used decolonization agents
are mupirocin for nasal carriage and chlorhexidine for
skin carriage [48]. Recent studies have identified decol-
onization  with  agents  such  as  chlorhexidine  and
mupirocin as having an important and perhaps under-
appreciated role in reducing Icu MRsa transmission:
Evens et al. could demonstrate that daily bathing of
trauma  patients  with  cloths  impregnated  with  2  %
chlorhexidine gluconate is associated with a decreased
rate of colonization by MRsa. and even more impor-
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less likely to develop MRsa VaP (1.6 versus 5.7 infec-
tions per 1000 ventilator-days, P = 0.03) [49]. climo et
al.  implemented  in  6  Icus  daily  bathing  with
chlorhexidine. the overall rate of MRsa acquisition
decreased 32 % during the intervention period in com-
parison with the baseline period [50]. It can be theo-
rized that reduced microbial density on a patient’s skin
led to decreased transmission to a healthcare worker’s
hands and thereby prevented subsequent transmission
to  additional  patients.  from  the  available  literature
octenidine appears to be as effective as chlorhexidine
for MRsa decolonization with fewer adverse effects,
but large randomised trials incorporating octenidine as
a skin disinfectant for MRsa decolonization are not
jet undertaken [51].
HaNd HygIENE aNd adEquatE staffINg lEVEls
already during the sixties several investigations stud-
ied the spread of S. aureus in hospitals. they identi-
fied the spread via the hands of the staff as the most
important way of transmission, and described the air-
borne way as less important [52]. therefore proper
hand hygiene is the crucial method for preventing the
spread of MRsa in hospitals. this was confirmed by
a cohort study by grundmann et al. to identify expo-
sures associated with cases that likely were the result
of cross-transmission (i.e., occurring in clusters and
with  indistinguishable  MRsa  macrorestriction  pro-
files) [53]. fitting a simple stochastic model to the as-
certained data allowed prediction of the effectiveness
of  infection  control  measures.  Exposure  to  relative
staff deficit was the only factor significantly associat-
ed with potential transmission (P =.001) and it was
predicted that a 12 % improvement in adherence to
hand-hygiene  policies  might  have  compensated  for
staff shortage and prevented transmission during pe-
riods of overcrowding, shared care, and high work-
load. Pittet et al. were able to demonstrate a signifi-
cant reduction of MRsa transmission rates in their
hospital by increasing the compliance to hand hygiene
substantially [54].  Meanwhile further studies demon-
strated the close association between increasing alco-
holic  hand  rub  consumption  and  decreasing  MRsa
rates [55].
PatIENt scREENINg
active surveillance cultures have been proposed to iden  -
tify MRsa carriers. carriers can receive contact precau-
tions and, if needed, decontamination, with the objec-
tive not only of decreasing their individual risk of in-
fection but also of diminishing the reservoir and, con-
sequently, the risk of cross‐transmission. In addition,
knowledge of MRsa carriage can be helpful for appro-
priate empiric or prophylactic antibiotic therapy [56].
Robinsec  et  al.  performed  an  observational  study
on  universal  MRsa  screening  in  3  hospitals  over  a
3.5‐year  period,  and  the  rate  of  MRsa  disease  de-
creased significantly [57]. In contrast, MRsa rate did
not decrease significantly during the intervention in 8
surgical units, where screening was performed routine-
ly at hospital admission, and MRsa carriers received
contact precautions and were recommended for decol-
onization and prophylactic antibiotic therapy [58]. a
meta‐analysis on MRsa screening found a nearly sig-
nificant 31 % decrease in the infection rate; the use of
rapid screening tests, however, was not found to be ef-
fective,  compared  with  conventional  culture‐based
methods  [59].    the  authors  concluded  that  active
screening for MRsa is more important than the type
of test used. But, they warned policy makers to make a
costly MRsa universal screening mandatory because
of the limits and the heterogeneity of the available ev-
idence.
HEaltH caRE woRkERs scREENINg
there is ongoing controversy about the role - as reser-
voirs, vectors, or victims - of health-care workers in
transmission of MRsa.  albrich et al reviewed 127 in-
vestigations showing an average MRsa carriage rate of
4.6  %  among  33,318  screened  health-care  workers
[60]. 5.1 % had clinical infections. Risk factors includ-
ed chronic skin diseases, poor hygiene practices, and
having worked in countries with endemic MRsa. the
authors recommend screening of health-care workers
during outbreaks and during early stages of an institu-
tional epidemic when MRsa prevalence is still low or
when  a  new  MRsa  strain  is  propagating  rapidly.  If
MRsa  is  detected  from  staff,  decolonization  proce-
dures should be applied. 
sINglE RooM IsolatIoN aNd ENVIRoNMENtal
clEaNINg
Many authors and guidelines recommend isolating pa-
tients with MRsa in single rooms in order to increase
compliance with hand hygiene and further barrier pre-
cautions like use of masks and gowns under isolation
conditions [61]. cooper et al. reviewed the evidence
for the effectiveness of different isolation policies and
screening  practices  in  reducing  the  incidence  of
MRsa  colonization  and  infection  in  hospital  in-pa-
tients. a total of 46 studies were included in their re-
view.  Most  were  interrupted  time  series,  with  few
planned  formal  prospective  studies.  all  but  one  re-
ported multiple interventions; no well-designed study
allows the role of isolation measures alone to be as-
sessed. despite major methodological weaknesses and
inadequate  reporting  in  published  research  the  au-
thors conclude that there is evidence that concerted
efforts that include isolation can reduce MRsa even
when  endemic  [62].  However,  in  2005  spread  of
MRsa  in  Icus  was  prospectively  investigated.  the
authors  concluded  that  moving  MRsa-positive  pa-
tients into single rooms or cohorted bays does not re-
duce cross-infection and they recommended re-evalu-
ating isolation policies [63]. on the other hand, con-
tact precautions are unlikely to help in a unit where
compliance with hand hygiene is very low at baseline.
apart  from  that,  many  authors  are  concerned,  that
isolation in single rooms for infection control precau-
tions  lead  to  patient  neglect  and  errors:  Healthcare
workers are half as likely to enter the rooms of pa-
tients in contact isolation, but are more likely to wash
their hands after caring for them than after caring for
patients not in isolation [64].  stelfox et al. examined
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isolated and non-isolated patients and found that iso-
lated patients experienced more preventable adverse
events,  expressed  greater  dissatisfaction  with  their
treatment and had less documented care [65]. Many
European  countries  have  been  using  isolation  mea-
sures for many years, but their MRsa rates continued
to increase. 
Healthcare workers can transmit MRsa via hands
or not changed gloves but also after touching contami-
nated environmental surfaces, since MRsa can survive
for  months  in  the  environment.  Neely  et  al.  tested
staphylococci: they survived for at least 1 day on all
fabrics and plastic. staphylococcal viability was longest
on polyester (1 to 56 days) and on polyethylene plastic
(22 to >90 days) [71].
8. coNclusIoN
the epidemiology of MRsa pneumonia varies across
countries. one of the most import risk factors for the
development of nosocomial MRsa pneumonia is me-
chanical ventilation. Methicillin resistance in s. aureus
VaPs ranged between 37 % in german, 54 % in the
us american and 78 % in asian and latin american
Icus. In 2009, the incidence density of nosocomial
VaP caused by MRsa was 0.28 per 1000 ventilation
days in a network of 586 german Icus. Incidences
peaked in neurological and neurosurgical Icus. crude
hospital mortality in studies performed after 2005 lay
between 27 and 59 % and attributable MRsa pneu-
monia  mortality  at  40  %.  since  2005,  us  american
and german data indicate decreasing trends for MRsa
pneumonia. Measures to reduce MRsa pneumonia or
to control the spread of MRsa include hand hygiene,
standard and contact precautions, oral contamination
with  chlorhexidine,  skin  decontamination  with  anti-
septics, screening, and (possibly) patient isolation in a
single room. lucet  et al. summarize that one of the
keys to a successful strategy is leadership, which en-
courages health care workers to adhere to recommen-
dations [56]. this factor probably makes a major con-
tribution to the success of infection control interven-
tions.
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